Document is current
Any future updates will be listed below
-
Authors
Ma, Lijiang
Tamis‑Holland, Jacqueline E.
Mocci, Giuseppe
Wolhuter, Kathryn
Bryce, Nicole S.
Sajja, Swathy
Amadori, Letizia
Pradhan, Payal
Chong, Peik Sean
Sukhavasi, Katyayani
Cheng, Haoxiang
Li, Ling
Pang, Shichao
Schadt, Eric E.
Schunkert, Heribert
von Scheidt, Moritz
Ruusalepp, Arno
Moreno, Pedro R.
Hao, Ke
Giannarelli, Chiara
Miller, Clint L.
Kovacic, Jason C. https://orcid.org/0000-0003-4555-769X
Björkegren, Johan L. M.
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01HL164577, R01HL148167, R01HL148239, R01HL166428, R01HL168174, R01HL153712, R01HL165258)
- License Information
-
More Information
Article History
Received: 8 September 2024
Revised: 9 March 2025
Accepted: 27 March 2025
First Online: 1 July 2025
Declarations
:
: JCK is the recipient of an Agilent Thought Leader Award (January 2022), which includes funding for research that is unrelated to the current manuscript. JLMB (the Principal Investigator in the STARNET study) is the founder and former CEO of Clinical Gene Networks (CGN), a privately-held company which seeks to commercialize clinical gene networks underlying coronary artery disease, myocardial infarction, and stroke. JLMB serves as Chairman of the Board, and owns equity in the company. JLMB also receives financial compensation as a consultant for CGN. The overall aim of the research collaboration is to investigate the activity of genes and their respective proteins in the cells of organs associated with ischemic heart disease/atherosclerosis and in vascular walls and metabolic organs such as skeletal muscles, fat tissue, and the liver. The ultimate aim is to use new knowledge to identify more accurate diagnostic methods and more effective therapies. The creation of biobanks is performed at Tartu University Hospital. The resources to study DNA, RNA, biopsy material and blood proteins are provided mainly by the Icahn School of Medicine at Mount Sinai (ISMMS) in New York and third parties. AR is also on the board of directors and a shareholder in CGN. Neither ISMMS nor CGN have made claims to results presented in this study. CLM received grant support from AstraZeneca for work unrelated to the current study.
